[Public Notice+] Sewon Cellontech Registers European Patent for High-Concentration Medical 'Bio Collagen'

[Asia Economy Reporter Hyunseok Yoo] Sewon Cellontech announced on the 22nd that it has completed European patent registration for high-concentration collagen (hereinafter referred to as ‘Bio-Collagen’) manufacturing technology intended for use as medical materials.

Dong-sam Seo, Head of Sewon Cellontech Regenerative Medical System Innovation Center, stated, “The ‘Bio-Collagen’ independently developed by Sewon Cellontech is characterized by maintaining the unique properties and structure of collagen naturally present in the body,” adding, “We have secured global patents in the US, Europe, China, and other regions for the core technology of ‘Bio-Collagen’ manufacturing and productization, and this patent represents an upgraded technology that further enhances the excellence of ‘Bio-Collagen.’”

The patent relates to technology for manufacturing medical (biomaterial) ‘Bio-Collagen’ that ensures ▲biological safety and sterility ▲high concentration and high purity quality.

Through a patented method involving strict multi-step processes such as extraction, purification, concentration, and mixing using precision filtration and tangential flow filtration (concentration after removal of low molecular substances), high-quality ‘Bio-Collagen’ is obtained. The ‘Bio-Collagen’ produced in this way can be used as a raw material for manufacturing various forms (liquid, sponge, powder) of regenerative medical products with excellent ▲biocompatibility ▲safety ▲tissue regeneration capabilities.

Center Head Dong-sam Seo emphasized the patent, saying, “It is important to note that this foundational technology enhances the performance of regenerative medical products and enables productization in various formulations, achieving technological evolution while opening up possibilities for industrial expansion,” adding, “This technology connects to the market potential in the regenerative medicine and biomaterials fields, where global demand is expected to expand. In line with this, the Regenerative Medical System Innovation Center is promoting a proactive market response strategy based on ‘RMS CAMP’ (Regenerative Medical System Innovation Center’s production and R&D hub).”

Sewon Cellontech is expanding infrastructure and establishing a mid- to long-term sustainable growth foundation through ‘RMS CAMP,’ currently under construction in Geumgok General Industrial Complex, to respond to growing domestic and international demand for RegenGraft (a therapeutic material used for treating various damaged human tissues) based on ‘Bio-Collagen’ and ‘Bio-Collagen’ raw materials.